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CHAPTER 2. 
INTRODUCTION 
 
Genetics in gastroenterology and clinical application. 
 
Throughout clinical medicine, recent progress in molecular 
genetics has provided critical insight into disease pathogenesis, 
guiding basic research into previously unforeseen areas.  
To better understand the relevance of genetic study in 
gastroenterology, first of all, we have to clarify the difference between 
monogenic disorders and complex diseases. The monogenic disorders 
are disease with mendelian inheritance, 
Complex diseases are those with polygenic factors involved in 
their pathogenesis, such as Chron and celiac disease. 
The analysis of monogenic disorders are most successful than 
complex disease. Possible strategies to identify candidate gene for 
monogenic gastrointestinal disorders could be based on functional or 
positional cloning. The first strategy starts from protein defect, the 
second one is based on the mapping of the gene in the genome and 
then in the identification of gene’s function (Figure 1). 
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Figure 1. Possible strategies to identify gastrointestinal disease genes. 
 
The identification of genes causing gastrointestinal disorders 
contribute to the understanding of disease’s pathogenesis, the rule and 
the interaction between proteins, and to better classify diseases. 
Otherwise, such discoveries have raised physicians’ and 
patients’expectations, particularly with respect to molecular genetic 
testing, but translating scientific progress to patient care needs careful 
evaluation. In specialist clinical genetics, protocols have been 
developed to ensure responsible molecular testing and detailed genetic 
counseling in fully penetrant single-gene disorders, however 
specialists in other disciplines, such as gastroenterology, perhaps 
remain less familiar with all of the complex issues surrounding genetic 
testing (Figure 2).  
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Figure 2. Impact of genomics in medical practice 
 
Several criteria must be satisfied for any genetic test before its 
application in clinical medicine. The test should ideally address a 
reversible risk, and thereby lead to clinically useful outcome; be 
socially and ethically acceptable to the individuals undergoing testing; 
have sufficient sensitivity and specificity; and be implementable and 
cost effective. 
In HNPCC and familial adenomatous polyposis (FAP), genetic 
testing not only carries the potential for identifying individuals or 
family members at risk, but also for directing the appropriate 
application of further intervention. 
Finally, genetic discoveries could be relevant to address future 
treatment, such as gene therapy or drug therapy. 
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Aim of this thesis was to explore the genetic component of some 
gastrointestinal disorders, such as dismotility disorders (Hirschsprung 
disease, esophageal achalasia and congenital intestinal pseudo-
obstruction) and intestinal polyposis, either by clinical study or by 
sequencing of candidate genes. Furthermore, my effort was addressed 
to develop a new strategy to stable trasduce intestine for future 
application such as gene therapy of gastrointestinal and no 
gastrointestional disorders.  
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CHAPTER 3. 
GENETICS OF DISMOTILITY DISORDERS. 
 
The enteric nervous system (ENS) is a collection of neurons in the wall 
of the entire gastrointestinal tract. It modulates and integrates the 
motility (1), microcirculation (2), secretion (3), and 
immune/inflammatory response (4). It consists in two major plexuses, 
the myenteric (Auerbach) and the submucosal (Meissner), otherwise 
associated neural elements connecting the ganglia and projecting to 
effector systems (muscles, interstitial cell of Cajal, glands, blood 
vessels and immune cells). The human ENS contains approximately as 
many neurons as the spinal cord (about 100 million) and is a 
specialized branch of the peripheral nervous system that can function 
independently from the central nervous system. The ENS is derived 
from specific axial levels of the neural crest (NC). Vagal, truncal and 
sacral NC cells colonize the gut in a rostral-to caudal progression 
during embryonic development. Truncal NC gives rise to ganglia in the 
esophagus and the proximal stomach, whereas the vagal NC gives rise 
to ganglia throughout the length of the gut. The entire colonization 
process is complete by approximately 13 week of gestation in humans. 
By the 24 weeks’ gestation, infants seem to have a full complement of 
the ENS neurotrasmitters, and at least partial ENS function is 
established. However, new enteric nerve cells continue to differentiate 
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at least throughout the first couple of years of life, suggesting that the 
young ENS continues to develop and change. Normal ENS 
development requires survival of NC derived cells and their 
coordinated proliferation, movement and differentiation into neurons 
and glias. All of these processes are influenced by the 
microenvironment of the developing gut. Defects in the NC derived 
cells themselves or alterations in the gut microenvironment may result 
in abnormal development of the ENS, such as Hirschsprung’s disease 
(HSCR), chronic intestinal pseudo-obstruction (CIP) and esophageal 
achalasia (EA). Although not yet fully elucidated, mutations in genes 
involved in these processes may also explain phenotypic variants of 
different motor disorder of the intestine, as those mentioned before, 
objects of this thesis.  
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3.1 HIRSCHSPRUNG’S DISEASE. 
 
3.1.1 Definition, epidemiology, pathophysiology and clinics. 
 
Hirschsprung's disease (OMIM 142623) is a heterogeneous genetic 
disorder, resulting from an anomaly of the enteric nervous system of 
neural crest cells origin, characterised by the absence of 
parasympathetic intrinsic ganglion cells in the submucosal and 
myenteric plexuses.  It is regarded as the consequence of the 
premature arrest of the craniocaudal migration of vagal neural crest 
cells in the hindgut, between the fifth and twelfth week of gestation, to 
form the enteric nervous system and is therefore regarded as a 
neurocristopathy (5).  
Hirschsprung’s disease occurs in approximately 1 of each 5000 live 
births and with a male predominance of 4:1. It is generally sporadic, 
although in 3-7% of cases a genetic trasmission has been reported (5). 
The risk for short segment disease is 5% in brothers and 1% in sisters 
of index cases; for long segment disease the risk is 10%, regardless of 
sex. (6)  
 The embryonic disorder is a lack of the craniocaudal migration, 
differentiation and maturation of neuroblasts from the neural crests, the 
earlier the migration ceases, the longer the aganglionic segment will 
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be. The aganglionic segment is permanently contracted, causing 
dilatation proximal to it (7). 
Hirschsprung’s disease may be classified according to the lenght of the 
aganglionic segment: the classic form (short segment 70-75% of cases) 
is limited to the rectum and sigmoid colon; the long segment, or 
subtotal colonic disease (10-15%), generally involves the bowel up to 
the splenic flexure;  total colonic aganglionosis (TCA: 3-6%) may 
extend to involve a variable amount of the short bowel. Total intestinal 
aganglionosis sometimes is associated with intestinal malrotation or 
volvulus (8). Ultrashort segment aganglionosis is considered a 
functional alteration, without any detectable histological finding.  
Although longer aganglionic segments tend to produce more 
drammatic symptoms, some patients with even short segment disease 
deteriorate rapidly (9). 
 The hallmark of diagnosis is the absence of ganglion cells from the 
myenteric and submucosal plexuses, as seen on a full-tickness or 
suction (mucosal-submucosal) biopsy of the rectum.  Proximal 
contents fail to enter the unrelaxed, aganglionic segment. The lack of 
non-adrenergic-non cholinergic inhibitory innervation is responsible 
for a tonic contraction of the affected segment, with absence of 
peristalsis and dilatation of the gut proximally. (10)  
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Morphologically, ganglion cells are absent from the narrowed segment 
and for some distance (1 to 5 cm usually) into the dilated segment.  
The pattern of nerve fibers is abnormal also; they are hypertrophic with 
abundant, tickned bundles.  Specific stains for acetylcholinesterase are 
used to highlight the abnormal morphology (11, 12). 
In the last years new insights in the pathophysiology of Hirschsprung's 
disease have been given.  There is a growing and emerging body of 
evidence that suggests that the disease can be the expression of a 
genetic alteration, as reported later on.  
 In the newborn, symptoms may appear during the first hours of life 
with failure to pass meconium, or in the first week with a picture of 
functional intestinal obstruction. However, the delay in the passage of 
meconium does not always occur and a percentage of children still 
present late or with complications despite a history of complications 
since birth.  Enterocolitis, the commonest complication, is always 
severe and is an important cause of mortality in these young patients. 
In infants and children the presentation is often less drammatic and 
may not mimic acute intestinal obstruction.  Severe constipation and 
recurrent fecal impaction are more common. Physical examination 
reveals a distended abdomen and a contracted anal sphincter and 
rectum in most children.  The rectum is devoid of stool except in cases 
of short-segment aganglionosis. As the finger is withdrawn, there may 
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be an explosive discharge of foul-smelling liquid stools,  with 
decompression of the proximal normal bowel.  
   
Abdominal radiographs show intestinal “cut-off” sign in rectosigmoid 
region with absence of air distally. Other common findings are small 
bowel dilatation in 74% and multiple air-fluid levels. (13) . Because of 
the risk of perforation,  contrast enema should not be performed in the 
presence of clinical enterocolitis.  
Rectal washouts should be the initial approach in the care of a child, 
regardless of age, who presents with enterocolitis. Along with 
washouts, intravenous antibiotics or oral metronidazole (in mild cases) 
should be used. Should the disease process fail to improve or the 
infants’s condition deteriorate, the performance of a leveling 
colostomy should be considered (14,15). 
 When the history (early onset of constipation, absence of faecal 
soiling) and/or the physical examination (empty rectal ampulla) 
suggest an organic cause, anorectal manometry should be performed. 
Anorectal manometry evaluates the response of the internal anal 
sphincter to inflation of a ballon in rectal ampulla (16).  When the 
rectal ballon is inflated, there is normally a reflex relaxation of the 
sphincter. The rectoanal inhibitory reflex is absent in patients with 
Hirschsprung’s disease; there is no relaxation, or there are may even be 
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paradoxical contraction of the internal anal sphincter.  The anorectal 
manometry is particulary useful when  the aganglionic segment is short 
and results of radiologic or pathologic studies are equivocal.  
Barium enema is helpful in the assessment of a transition zone 
between aganglionic and ganglionic bowel and in giving an estimation 
of the lenght of an aganglionic segment. Demonstration of the 
transition zone is easier if no effort is made to clearance the bowel. In 
the newborn, dilatation of the proximal ganglionic bowel may not have 
developed and radiological diagnosis may be more difficult. The 
sensivity and specifity for recognition of a transition zone have been 
reported to be 80% and 76%, respectively (17). The barium enema may 
not show a transition zone in cases of total colonic Hirschsprung’s 
disease, or may be indistinguishable from cases of functional 
constipation when ultra-short-segment Hirschsprung’s disease is 
present. 
Nevertheless, the diagnosis is based on histological evidence. Since 
the mid 1970s, demonstration of acetylcholinestease activity in 
mucosal biopsies has allowed the non invasive suction rectal biopsy 
thecnique to become the most reliable diagnostic method for 
aganglionosis (11,12). 
 The treatment of Hirschsprung’s disease is to resect the 
aganglionic segment of the rectum and colon, pull down normally 
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innervated bowel, and anastomose this bowel at the anorectal region, 
while preserving the sphincter muscle.  Recently minimally invasive 
approaches to the 1-stage pull-through have became popular.  The one-
stage approach, even in the newborn period, either by laparotomy or by 
combined laparoscopy and transanal dissection, has been advocated.   
 Some patients with Hirschsprung’s disease continue to have 
problems postoperatively, this may be because of residual disease or 
association with neuronal dysplasia. If the definitive operation fails 
because of an impassable stricture, disruption or residual disease, 
further secondary surgery may be necessary and a different operation 
may then lead to a reasonable result.  
 
3.1.2 Genetics of Hirschsprung’s disease. 
 HSCR occurs as an isolated trait in 70% of patients, is associated 
with chromosomal abnormality in 12% of cases, trisomy 21 being by 
far the most frequent (>90%). Additional congenital anomalies are 
found in 18% of cases, including gastrointestinal malformation, cleft 
palate, polydactyly, cardiac septal defects and craniofacial anomalies. 
The higher rate of associated anomalies in familial cases than in 
isolated cases (39% vs 21%) strongly suggests syndromes with 
Mendelian inheritance (18). Isolated HSCR appears to be a 
multifactorial malformation with low, sex dependent penetrance, 
Genetics of gastrointestinal diseases 
 
16 
 
variable expression according to the length of the aganglionic segment, 
and suggesting the involvement of one or more gene(s) with low 
penetrance (19). These parameters must be taken into account for 
accurate evaluation of the recurrence risk in relatives.  Segregation 
analyses suggested an oligogenic mode of inheritance in isolated 
HSCR. With a relative risk of recurrence as high as 200, HSCR is an 
excellent model for the approach to common multifactorial diseases.  
A large number of chromosomal anomalies have been described in 
HSCR patients. Free trisomy 21 (Down syndrome) is by far the most 
frequent, involving 2-10% of ascertained HSCR cases. Syndromes 
associated with HSCR can be classified as: (1) pleiotropic 
neurocristopathies, (2) syndromes with HSCR as a mandatory feature, 
(3) occasional association with recognisable syndromes.  
 The neural crest is a transient and multipotent embryonic structure 
that gives rise to neuronal, endocrine and paraendocrine, craniofacial, 
conotruncal heart, and pigmentary tissues. Neurocristopathies 
encompass tumours, malformations, and single or multifocal 
abnormalities of tissues mentioned above in various combinations.  
Multiple endocrine neoplasia type 2 (MEN 2), and Waardenburg 
syndrome are the most frequent neurocristopathies  associated with 
HSCR (20).  
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Waardenburg syndrome (WS), an autosomal recessive condition, is by 
far the most frequent condition combining pigmentary anomalies and 
sensorineural deafness, resulting from the absence of melanocytes of 
the skin and the stria vascularis of the cochlea. The combination of 
HSCR with WS defines the WS4 type (Shah-Waardenburg syndrome). 
Indeed, mutations of the endothelin pathway and SOX10 mutations 
have been identified in WS4 patients with CNS involvement including 
seizures, ataxia, and demyelinating peripheral and central neuropathies 
(21).   
 Eight genes are known to be involved in HSCR in humans, those 
encoding for the proto-oncogene RET (RET), glial cell line derived 
neurotrophic factor (GDNF), neurturin (NTN), endothelin B receptor 
(EDNRB), endothelin 3 (EDN3), endothelin converting enzyme 
1 (ECE1), SOX10, and SIP1 genes. RET and EDNRB signalling 
pathways were considered biochemically independent. However, an 
HSCR patient heterozygous for weak hypomorphic mutations in both 
RET and EDNRB has recently been reported (22). Each mutation was 
inherited from a healthy parent. SOX 10, otherwise, is involved in cell 
lineage determination and could be responsible of the reduced 
expression of EDNRB in the dom mouse.  
 The last de novo mouse model for the human WS4 is dominant 
megalon (Dom). The Dom gene is Sox10, a member of the SRY (sex 
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determining factor)-like, high mobility group (HMG) DNA binding 
proteins. Subsequently, heterozygous SOX10 mutations have been 
identified in familial and isolated patients with WS4 (including de 
novo mutation) with high penetrance (23).  
 
3.1.3 Aim of the project. 
 
Aim of our study was first of all to clinically characterize the 
Hirschsprung disease in children trying to identify new syndromic 
phenotype associated with HSCR;  secondly to make a mutational 
analysis of  some genes (SOX10 and ZFX1B) already involved in 
syndromic HSCR and to make a possible phenotype-genotype 
correlation. My personal contribution was on clinical examination of 
HSCR patients. 
 
3.1.4 Paper in submission. 
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Immacolata Maresca1, Eleonora Giannetti1, Antonino Tramontano2, Gianfranco Sebastio1, 
Annamaria Staiano1 
 
1Department of Pediatrics, University “Federico II”, Naples. 
2Ospedale Santobono 
 
 
Introduction. 
Hirschsprung disease (HSCR) is a congenital malformation characterized by the absence of neurons 
in the distal colon with symptoms ranging from neonatal intestinal obstruction to chronic 
constipation1. HSCR is attributed to the failure of neural crest cells to completely colonize the 
intestinal tract during the 4th to 12th weeks of gestation, and hence is termed a neurocristopathy2. 
The absence of the intramural ganglion cells is at level of both the myenteric and submucosal 
plexuses . Patients can be classified as rectosigmoid HSCR (RS, 78% cases) when the aganglionic 
segment does not extend beyond the upper sigmoid, long segment HSCR (LS, 32% of cases), when 
aganglionosis extends proximal to the sigmoid and total colonic aganglionosis (TCA, 3-8% of 
cases), when aganglionosis extends within 30 cm proximal to the terminal ileum3. In most cases, the 
diagnosis of HSCR is made in the newborn period owing to intestinal obstruction, such as failure to 
pass meconium within the first 48 hr of life, abdominal distension, vomiting4, 5. Some patients are 
diagnosed later with severe constipation and/or diarrhea, chronic abdominal distension, vomiting, 
and failure to thrive4. The diagnosis of HSCR is based on the absence of relaxation of internal anal 
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sphincter, after the 12th day of life, revealed by the anorectal manometry6. Suction rectal biopsy 
confirms the diagnosis in most cases, but a full thickness rectal biopsy is needed for diagnosis of 
HSCR7. The following criteria, obtained on suction rectal biopsy specimens, represent the gold 
standard of the diagnosis of HSCR: the absence of ganglion cell, replaced by hypertrophic nerves 
with no network. These hypertrophic nerves are responsible for increased acelylcholinesterase in 
the aganglionic bowel8, 9. The incidence of HSCR is estimated at 1/5000 live births with a 4:1 male 
predominance10. HSCR occurs as an isolated trait in 70% of cases11. A chromosomal abnormality is 
associated with it in 12% of cases, trisomy 21 being far the most frequent (>90%)11. Associated 
congenital anomalies have been found in 18% of HSCR patients11. In many cases of HSCR 
associations, neurocristopathies and syndromes, the underlying genetic links are already known  or 
suspected.  
Because it is generally accepted that the pattern of associated lesions may throw some light on 
possible genetic associations of the disease12, 13, aim of our study was to clinically characterize the 
Hirschsprung’s disease in children, to make a mutational analysis of  some genes (SOX10 and 
ZFX1B) already involved in syndromic HSCR and to correlate phenotype to genotype.  
 
Patients and methods.  
Patients and clinical evaluation. 
From January 2004 and June 2005 we have enrolled 48 HSCR patients (mean age.......), diagnosed 
by the absence of  the anorectal inhibitory reflex revealed by the manometry and by the presence of 
the two histological criteria, absence of ganglion cells and presence of acetilcholinesterase fibers, 
on a suction rectal biopsies. A complete clinical evaluation was performed by using a specific 
questionnaire for the anamnesis, collecting data on time of beginning of symptoms, type of 
symptomatology, length of the aganglionic segment, familial anamnesis, symptoms associated. To 
get a better clinical characterization all the patients underwent an oculistic, audiometric, orthopedic 
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and neurological examination and, after parental consens, a blood sample was obtained for 
karyotype and DNA extraction for genetic analysis. 
 
Anorectal manometry.  
This test was carried out without sedation and after complete clearance of the lower bowel. A Dent 
sleeve catheter with at least three silicon lumens with side holes (outside diameter, approximately 
2.0 mm), perfused with a low compliance pneumohydraulic system at a rate of 0.5 ml/min, was 
used. A latex balloon (2.5 cm x 3.0 cm) was attached to the end of a thin silicon lumen and tied to 
the tip of the motility probe, 5 cm above the distal transducer. Pressures from the latex balloon and 
from the side holes were transmitted via the silicon tubes to pressure transducers. The outputs for all 
transducers were fed into a poligraph (MMS UPS-2020 Medical measurement system for 
investigation of gastrointestinal motility) and graphed on running paper. The anorectal pressure 
profile and the effect of rectal distention were evaluated. The response of the anal canal to rectal 
distention was evaluated with the base of the distending balloon 11 cm above the anal verge, one 
pressure transducer in the rectum 6 cm above the anal verge, and another in the anal canal 1 cm 
above the anal verge. With sudden rectal distention, in normal children, the external sphincter 
contracts and the internal anal sphincter relaxes. This relaxation of the internal sphincter results in 
reduced anal pressure. This phenomenon is referred to as anorectal inhibitory reflex, and it is absent 
in HSCR. 
  
Suction rectal biopsy. 
 In all patients, diagnosis of HSCR was based on both hematoxylin-eosin (H&E) and histochemical 
acetylcolinesterase (AchE) staining on two suction rectal biopsies performed by Noblett capsule. 
Suction rectal biopsies were taken at least 2 cm above the pectinate line and were kept moist on 
saline-soaked filter paper in a small Petri dish. One biopsy was embedded in O.C.T. (Bio-Optica), 
snap frozen for cryostat sectioning in a plane perpendicular to the mucosal surface, and stored at -
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80°C. Ten micrometer-thick sections, oriented to obtain longitudinal sections, were cut at -23°C 
with a cryostat microtome (Cryostat HM560MU), until submucosa was visible, then mounted on 
slides and stained with H&E and AchE stainings. In the AChE staining iso-OMPA was used instead 
of OMPA. The other biopsy, kept in formalin, was wax-embedded, cut and stained with H&E. 
Histochemical criteria to establish HSCR diagnosis include: absence of ganglion cells in sub-
mucosa, presence of nerve trunks in sub-mucosa, increased AChE-positive fibers in muscularis 
mucosae and sub-mucosa.  
 
Analysis of sequences of the genes SOX10, ZFX1B (fare correggere a Sebastio) 
Specific primers for SOX10 not available from the literature, were designed in the intronic regions 
in order to amplify, by PCR on genomic DNA, both the coding regions and the intron-exon 
junctions. These primers were designed by the analysis of the genomic sequences of the two genes 
deposited in Genbank and optimized for a single condition of amplification. Briefly: denaturation 
for 1 min at 94°C, hybridization for 1 min. at 52°C, elongation for 1 min. at 72°C. The primers for 
the amplification of the exonic regions and of the intron-exon junctions of ZFX1B were already 
reported11, 14. The PCR products were purified and direct sequenced, on both directions, using an 
ABI PRISM Dye Terminator Cycle DNA sequencing Kit and an automatic sequencer (ABI PRISM 
377, Applied Biosystems). Primers used for the amplification are available on request. 
 
Results. 
We included in our study patients, who received the diagnosis of HSCR based on absence of  the 
anorectal inhibitory reflex revealed by the manometry and on the presence of the two histological 
criteria, absence of ganglion cells and presence of acetilcholinesterase fibers, on a suction rectal 
biopsies. From January 2004 to June 2005 we enrolled 48 HSCR patients. The oculistic 
examination was performed in 43/48 patients, the audiometric exam in 37/48 patients. The 
orthopaedic evaluation was done in twelve patients and the neurologic visit in only patient. The 
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karyotype analysis was performed in 39/48 patients, the DNA was extracted by 46/48 patients and 
from 6 pairs of parents in the familiar and syndromic cases. We found in our population 10 cases of 
familial HSCR (20.8%) in 5 different families. One of these families have 3 subjects affected by 
Shah-Waandenburg’s syndrome. In the remaining patients, 21 were sporadic HSCR (43.75%), 3 
(6.25%) are Down’s patients and 15 (31.25%) had one or more anomalies associated with HSCR. In 
particular, skeletal-muscle-limb anomalies were found in 20.3%, dysmorphysms in 25%,  skin and 
integumentary and urogenital anomalies in 6.25%, RPSM, cardiac and gastrointestinal anomalies in 
4.1% and ophthalmic and hearing problems in 2.08%, (Fig.1). We have also found that the longest 
traits of aganglionic colon have been found in patients with HSCR associated with other anomalies 
more frequently than in simple sporadic HSCR (39% vs 6%) (Fig.2, panel A and panel B). Five 
patients on 15 with HSCR with associated anomalies  have an affected familiar (33%), as already 
reported in the literature. This means that the mendelian transmission is confirmed. Sequencing of 
the coding regions and the exon-intron boundaries of ZFX1B did not show nucleotidic changes, 
whereas analysis of the SOX10 gene revealed 2 polymorphisms, C566A in exon 3 (Gly188GLy), 
T1205C in  exon 5 (His401His), respectively, and a nucleotide substitution G2154A in the 3’ 
untranslated region. 
 
Discussion. 
Associated congenital anomalies occur in at least 5-32% of HSCR patients. These associations are 
of significance due to at least two reasons: firstly, the majority may be attributed to abnormal 
genetic development signalling, yielding clues as to the genetic background of HSCR and its 
pathogenesis and, secondly, the influence of associated anomalies on the long-term prognosis. 
Essentially, HSCR is caused by defects at a molecular level of normal signalling during enteric 
nervous system’s development. As a consequence, the cues controlling the migration of the neural 
crest cells go awry resulting in aganglionosis of the distal bowel. The disorder is complex, as is 
shown by the number of genes implicated in its pathogenesis (at least 11). The pattern of conditions 
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associated with HSCR have already been of great value in revealing many of the genetic 
associations of the disease (Spounge, 1985) with known genetic variations being identified in at 
least 12% of HSCR cases (Bolk S 2000, Carrasquillo MM 2002) which is higher than what is 
expected in the normal population. In addition, these genetic variations are associated with more 
than 50% of the observed abnormalities associated with HSCR. On the other hand, it must be borne 
in mind that certain observed associations may not  be higher in HSCR than in general population 
and may have little to do with HSCR per se. By looking at associated birth defects of a genetic 
condition, information can be gleaned not only on how the genes control development work but also 
on how they interact and crosstalk through gene-gene interaction whilst remaining genetically 
distinct. The incidence of associated congenital anomalies has been noted to be relatively low in a 
number of series and are interestingly enough, not frequently associated with familial transmission 
(Moore SW 1991, Brown RA 2000). 
In our study, the associated physical anomalies were less frequent in the familial than in the 
sporadic HSCR (33% vs 67%). Individual anomalies vary in incidence from 2.08% to 25% (Fig.1), 
the most frequent being dysmorphysms and skeletal-muscle-limb anomalies (25 and 20.3%, 
respectively). Less frequent are genitourinary and skin anomalies (6.25%) closely followed by those 
related to heart, central nervous system and bowel (4.1%). Although ocular and hearing 
abnormalities are important, they represent only the 2.08%.  
Possible genetic associations for HSCR disease could be hypothesized  considering that major RET 
mutations may give rise to HSCR by haploinsufficiency (20-25% of cases), the majority of HSCR 
probably arise from the multiplicative combined effects of other susceptibility genes and mutations 
(11) and the final phenotypic expression seems to depend on the combined cumulative effects of the 
susceptibility loci at critical genes that control the mechanisms of cell proliferation, differentiation 
and maturation (Mc Callion AM, 2003). Study of known critical sites should include the potential 
modifying role of significant genes flanking the critical areas which may affect the final phenotypic 
expression of HSCR. Our study on the anomalies associated with HSCR can contribute much 
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towards the identification of candidate genes and the underlying of complex mechanisms of cell 
proliferation, differentiation and maturation of enteric neuroblasts and of the pathogenesis of 
HSCR. 
As an important consequence, assessment of all HSCR patients should include a careful clinical and 
genetic evaluation.  
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3.2 CONGENITAL INTESTINAL PSEUDO-OBSTRUCTION. 
3.2.1 Definition, epidemiology and clinics. 
The term chronic intestinal pseudo-obstruction (CIP) describes a 
disorder of gastrointestinal motility characterized by failure of the 
intestine to propel its contents through an unobstructed lumen (24). It 
has been estimated that approximately 100 infants with congenital CIP 
are born each year (24). Symptoms include persistent nausea, 
vomiting, abdominal distention, weight loss and constipation (25,26). 
Diarrhea caused by either bacterial overgrowth or a hypersecretory 
state may also occur  (27). Symptoms may be intermittent or 
continuous and in the most severe forms often there are signs of an 
intestinal obstruction (such as dilated bowel loops or air-fluid levels) 
in the absence of a fixed lumen-occluding obstruction (28). In most 
cases, CIP results in a irreversible disorder of intestinal motor 
function, with the management consisting of nutritional support, use of 
prokinetics agents and prevention and treatment of bacterial 
overgrowth. Gastrostomies and jejunostomies may also be used for 
slow administration of enteral formulas. Referral for intestinal 
transplantation should be considered in the presence of frequent septic 
episodes, limited intravenous access for nutritional support and 
impending liver failure (29). 
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3.2.2 Pathogenesis and genetics of CIP 
  There is no single pathogenic cause for CIP in children. It is 
classified  in primary and secondary CIP. Based on histopathology or 
manometric findings, patients with primary form have traditionally 
been subdivided into neuropathic (affecting primarily the nerves in the 
intestinal tract or demonstrating a disorganized pattern of intestinal 
motility) and myopathic form (affecting primarily the muscle of the 
intestinal tract or demonstrating diminished amplitude of coordinated 
contractions) (30). But the list of conditions and possible causes that 
have been associated with symptoms of CIP continues to expand 
(Tab.1) 
Primary forms 
• Visceral neuropathy: sporadic or familial 
• Visceral myopathy: sporadic or familial 
 
Secondary forms 
• Muscular dystrophy 
• Scleroderma and other connective tissue disease 
• Postischemic neuropathy 
• Postviral neuropathy 
• Hypothyroidism 
• Diabetic neuropathy 
• Severe IBD 
• Organ Transplantation 
• Amyloidosis 
• Chagas’ disease 
• Prenatal alcohol exposure 
• Chromosomal abnormalities 
• Multiple endocrine neoplasia IIB 
• Radiation enteritis 
Tab 1. Classification of CIP 
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A genetic basis is suggested by some family clustering of CIP. Tanner 
reported one genetic form of CIP resulting from qualitative 
abnormalities of the enteric ganglia and nerve fibers. This histological 
phenotype suggests the presence of a differentiation defect. An 
autosomal recessive inheritance was supposed for this type of CIP 
occurring as a syndrome presenting with short small bowel, 
malrotation and pyloric hypertrophy associated with morphologic 
defects of argyrophil neurons in the myenteric plexus (31).  
In 1996, it was described a family in which the chronic idiophatic 
intestinal pseudo-obstruction appeared to be segregating as an X 
linked recessive trait (CIIPX- OMIM 300048) and in which the 
disease locus was mapped to Xq28. The microsatellite markers, 
located in the distal part of Xq28, showed no recombination with a 
maximum lod score of 2.32. On the analysis of recombinants, the 
authors concluded that the critical region for the disease gene was 
limited by DXS15 toward the centromere and by DXYS154, the 
pseudoautosomal boundary toward the telomere (32). One year later, it 
was described another family with two brothers  and a maternal uncle 
affected with CIP. All three had a patent duct arteriuos  and chronic 
thrombocytopenia (33). One of the brothers and maternal uncle had 
gut malrotation, already described in the Italian family by Auricchio, 
suggested that gut malrotation may be a useful phenotypic marker for 
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an X-linked form of CIP. DNA analysis of this pedigree demonstrated 
cosegregation of the maternal grandamother Xq28 haplotype with the 
disease, confirming Auricchio’s results.  
 
3.2.3 Aim of the project 
Aim of this part of the project has been the identification of the gene 
mutated in CIIPX and located in the CIIPX critical region in Xq28. 
 
4.2.4. Paper published. 
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3.3 ESOPHAGEAL ACHALASIA 
 
 
3.3.1 Definition, epidemiology  and clinics. 
 
The esophageal achalasia is the most recognized motor disorder of the 
esophagus . The disorder is characterized by the partial or complete 
loss of lower esophageal sphincter (LES) relaxation after 
physiological stimulus and loss of esophageal peristalsis. An increase 
in LES resting pressure may also be present (34). This disease 
produces characteristic manometric and radiographic features (35,36). 
Achalasia remains an uncommon but worldwide disorder. The 
incidence of the disease is about 1/200000 per year and it has an equal 
frequency in men and women in all age groups; however, fewer than 
5% of all patients with achalasia manifest symptoms, such as 
disphagia, before the age of 15 years (0.11 case per 100000 
children)(37). 
 
3.3.2 Pathogenesis and genetics of esophageal achalasia. 
Numerous theories exist regarding pathogenesis, but a 
degenerative lesion involving intramural nitric oxide-containing 
inhibitory neurons in the distal esophagus and LES appears to be 
central to the disease. Lack of the inhibitory influence prevents the 
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normal sequencing of the distal contractions (resulting in aperistalsis) 
and normal relaxation of the LES with swallowing (38). 
Pharmacological and histological studies have shown that neuron 
degeneration is due to inflammatory and fibrotic process (39). The 
etiology of these phenomena remains unknown, but both genetic and 
immunologic factors presumably are relevant. Some data support an 
immunological basis for achalasia. Infact, early achalasia patients and 
end-stage achalasia patients, who underwent esophagomyotomy and 
esophageal resection respectively, showed a myenteric inflammation 
resulting from an immunologic process as the major cause of the 
myenteric neuronal degeneration (40). The majority of myenteric 
inflammatory cells in patients with achalasia are CD3-positive T cells, 
most of which are also CD8-positive, although the relative percentage 
of such cells appears to decrease with disease progression. 
Furthermore, many of the CD3-positive/CD8-positive myenteric 
lymphocytes also express activation markers, suggesting they are 
resting or activated cytotoxic T cells. The immunohistochemical 
demonstration of the granzyme B in a subpopulation of these cells 
supports the contention that achalasia is an immune-mediated disease, 
although the inciting antigen remains an enigma (40). Also, in animal 
models with megaesophagus it has been shown that the muscolar layer 
of the dilated portions shows a focal inflammation and single fiber 
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necrosis (41). The stimulus for this inflammatory reaction is still not 
completely understood but may be driven by autoimmune factors. 
Presumably  participating in the process, autoantibodies against M2 
muscarinic acetylcholine receptors have been found in patients with 
achalasia. These antibodies increase the contractile activity of the LES 
through specific activation of the receptors (42). 
In many cases, the achalasia have a clear genetic component, for 
example in early diagnosis case (before 6 months of age) and in 
familial cases, in which autosomal recessive inheritance is suggested 
(OMIM 200400). In literature, it has been described about 8 families 
with 21 affected members, in the majority they were pediatric patients 
with achalasia diagnosis before the age of 10. Four of these patients 
were also syndromic (43-49). In the same families, there were also 
some relatives with esophageal symptoms without a clear achalasia 
diagnosis (50). 
An achalasia-like picture also accompanies a variety of genetically 
based syndromes, where in the pathophysiologic mechanisms 
responsible for the esophageal manifestations may vary but reveal a 
genetic basis. For example, achalasia is associated with the 
autoimmune poliendocrine syndrome (APS1) (51), the 
megaduodenum (52,53), the multiple endocrine neoplasia (MEN2B) 
(54), the peripheric motor neuropathy with disautomomy (55), the 
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vulvar leiomiosis with or without nefropathy(56), the Down's 
syndrome, the Sjogren's syndrome, the Allgrove's syndrome 
(achalasia, alacrima, adrenal insufficiency). Maybe, these last two 
syndrome might be caused by the same genetic mutation in the aladin 
gene, located on chromosome 12q13 (57-59). 
One important genetic factor for the pathogenis of achalsia is the 
HLA-DQ, in particular alleles DQA1-0103 and DQB1-0603 (60-62). 
Furthermore, in those patients with this HLA alleles it has been found 
a greater prevalence of the myentric anti-plexus antibodies (42). 
Recently, it has been shown that collagenous networks play a critical 
role in the morphogenesis of the embryo and in the maintenance of the 
tissue architecture of adult tissues. The 19 genetically distinct types of 
collagen molecules are expressed in developmental and tissue-specific 
manners (63-66). In particular, type XIX collagen is a poorly 
characterised extracellular matrix component thought to be involved in 
the formation of specialized basement membrane zones (vessels, 
nerves and mesenchima). XIX collagen is important for the cell-to-cell 
interaction, the communication between cells and the local 
concentration of signalling molecules. This gene expression was for 
the first time studied in the mouse (Col19a1) and it was demonstrated 
the transient expression quite only in the embryonic muscle (67). Like 
the myogenic regulatory factor myf-5, Col19a1 transcription gradually 
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decrease in differentiating skeletal muscle progenitors and 
concomitantly to increased myogenin gene expression (68). This 
results show that Col19a1 could be involved in the muscle 
differentiation and function. The transient expression of Col19a1 in 
muscular tissue is confined to a few sites of the developing embryo, 
such limbs, tongue and smooth muscle layer of the stomach and 
esophagus, but also in skin and cerebral cortex and hippocampus of 
the new born brain. Unlike all other tissues, expression of Col19a1 in 
the central nervous system gradually increases after birth (68). 
 
3.3.3 Animal models for esophageal achalasia. 
More recently, two animal models have been created, one harbouring 
null and the second structural mutations of Col19a1, to reveal the 
critical contribution of this matrix protein to muscle physiology and 
differentiation(69). The null mice died in the majority after 3 week of 
postnatal life, showing signs of malnourishment. The few mice that 
survived past weaning stage revealed a dilated esophagus 
(megaesophagus) with retention of ingesta, immediately above the 
diaphragm level. The embryonic Col19a1 expression coincided with 
the formation and growth of the gastroesophageal junction. 
Specifically, in situ hybridizations revealed high Col19a1 expression 
in the lower-third portion of the embryonic esophagus destined to 
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become the abdominal segment; thereafter Col19a1 activity becomes 
gradually restricted to the mature LES, while decreasing in the muscle 
layer of the proximal stomach. Furthermore, intraluminal pressure 
recorded at the LES level of adult Col19a1 null mice showed 
significantly higher basal tone (three to eightfold) than wild-type mice. 
It also documented severely impaired or absent relaxation upon 
swallowing; even when present, relaxation was abnormally brief. The 
results of the manometric tests were remarkably similar to those 
reported for achalasic patients. The phenotype includes also an 
impaired nitric oxide-dependent relaxation of the sphinteric muscle, 
correlated with a disorganizied matrix and a normal complement of 
the enteric neurons and interstitial cells of Cajal. Null mice showed 
also an impaired smooth-to-skeletal muscle cell conversion in the 
abdominal segment of the esophagus, accounted for by failed 
activation of myogenic regulatory factors that normally drive 
esophageal muscle transdifferentation. In conclusion, all the data 
demonstrate that COL19A1 is an important gene for the LES 
development and function, and for this reason it could be involved in 
the pathogenesis of esophageal achalasia in men. 
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3.3.4 Aim of the project. 
 
Aim of this part of the project was to analyze the potential 
involvement of mutation at the COL19A1 locus in the pathogenesis of 
esophageal achalasia.  
 
Patients and Methods. 
Patients. 
44 adult patients (mean age: 27 years) and one pediatric patient (9 
years old) affected by sporadic esophageal achalasia and one adult 
patient with a familial form of EA (also the father was affected by 
EA) have been enrolled in this study. Diagnosis have been made by 
clinical and manometric  criteria. A blood sample was collected from 
each patient for genetic analysis. In two cases, in which mutation 
analysis have been successufully concluded, a blood sample was 
obtained from relatives (Fig. 3, Panel A and Panel B). 
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Fig.3 Pedigrees of the two patients carriers of COL19A1 mutations 
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Sequencing of COL19A1 gene.  
First, we have performed genomic DNA extraction from peripheral 
blood collected from all patients affected by EA using standard 
protocol. Specific primers for COL19A1, not available from the 
literature, have been designed in the intronic regions in order to 
amplify, by the PCR, both the coding regions and of the intron-exon 
junctions (Tab.2). These primers have been designed by the analysis 
of the genomic sequences of the gene deposited in the GenBank and 
optimized for a single condition of amplification and to produce 
fragments of about 500 bp. Briefly, the PCR protocol will be: 
denaturation for 1 min at 94°C, hybridation for 1 min at 54°C, 
elongation for 1 min at 72°C. The PCR products have been direct 
sequenced using an automatic sequencer (ABI PRISM 377, Applied 
Biosystem). The sequences have been analyzed by Autoassembler 4.1 
or SeqMan programs. 
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Fragment 
 
Exon 
                      Primers Lung.
Fram. 
Tm 
calc. 
Tm 
eff. 
COLg1 1 5’ TGCATCCAACCGTCATTTTATC 
3’ GAACACGAGCAGATGACATAG 
350 62/62 58 
COLg2 2 5’ CGTTGATTGGTTTTGCTTTGGT 
3’ CTATGGCCTTTTCAATCTTAAC 
287 62/62 58 
COLg3 3 5’ AAGTAACCACATGTAACCCTCA 
3’GCTATGATCTTAAATTGCAGTAT 
342 62/60 58 
COLg4 4 5’ GTTTCTCAATAGCATCATCCTC 
3’ CACTGTAGAGCCAAGATTAGATT 
309 64/62 62 
COLg5 5 5’ TTTCTTGCAATCTCCAGTTTCC 
3’ CCATCCTAACTACGAGAATACT 
319 62/62 58 
COLg6 6 5’ TTTTGTAGTGGTGTTTGCTGTT 
3’ CTCTTTCACAACTAACATCACA 
462 60/60 58 
COLg7 7 5’ TCCACAAAACAATGAATCCTAC 
3’ AATTACCCACCTGGCTTCAAC 
348 60/62 54 
COLg8 8 5’ GGAAAGTGCAAAAGTGTGATAA 
3’ AAACACTGAATGGCAAGACACA 
380 60/62 58 
COLg9 9 5’ CCAGCTTCACATTTATAAACCA 
3’ ACACCAGCCTACCAATATGAAT 
325 60/62 58 
COLg10 10 5’ GAGAAATAAGGAACAGATGGAA 
3’ TGTGATAAAGCTTCCTCCTAGA 
382 60/62 58 
COLg11 11 5’ GGTTTAGAGCTTACATGTTAGA 
3’ AGGGAATGCACAAAACAAGTTAA 
252 60/62 58 
COLg12 12 5’ TTGGTTTTACGACTCAGGATTG 
3’ AAACTAAAAACACTGGGCCTCT 
365 62/62 58 
COLg13 13 5’ TTATCATTTTAGTGCCAGTTGT 
3’ TTTAGAATGCTTTTAGGAGATA 
293 58/56 58 
COLg14 14 5’ GAAAGCTAAAAGGGACATGATA 
3’ TGGATAATAAACAGAATAATGGA 
248 60/58 58 
COLg15 15 5’ CAAAGAAGCCAGTCAAAGAAGG 
3’ ATATGCCCATCTGCTTGCTCTA 
324 64/64 62 
COLg16 16 5’ TTTAAAAGTCATGTGGAATTGG 
3’ AAACCAGTCATTCTAAACAGTA 
300 58/58 52 
COLg17 17 5’ ATATTTGTCTTTGATTTGTTTA 
3’ ACTGAACAGAATACTTTTTTTA 
254 52/54 52 
COLg18 18 5’ ACTTGAGAATAGGGAGAGCAGAT 
3’ TTATAGTGAGCCAAGATTGTGCC 
489 66/66 66 
COLg19 19 5’ AGTTAGCAGGAGAGCAAGCAAT 
3’ AACCTCTTTATGCCTTACTTTCA 
397 64/62 58 
COLg20 20 5’ TGGGTATTTTTGGAGGTCTGTT 
3’ CAATGTATTAGAAAACTCAAACC 
376 62/60 58 
COLg21 21-22 5’ ATGAACTCTCCTTGATTTTATTG 
3’ CCAAAAGACAGTTACTATGCGT 
490 60/62 58 
COLg22 23 5’ GATAAAGTGGGAAAGTGGGATG 
3’ TTAGGTATGATCAGTTTTTGTGG 
319 64/62 58 
COLg23 24 5’ AAACAACAAACCACGTAGAATCA 
3’ TCTCTTCCTCCTATCTACTTAAC 
219 62/64 58 
COLg24 25 5’ AATGTAAATGGCACCCCCTAGA 
3’ GCAGACCTAAACTTATTCCCAT 
463 64/62 62 
    COLg25 
 
         26 5’ CTCCCCGTTCCTTATTCTTTTAT 
3’ CCTTTCTATTCTTTTCTCCTTGT 
 438 64/62 58 
Tab. 2. COL19A1 PCR primers used. 
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4.3.4 Results. 
 
We have found two mutations (changing in DNA sequence, absent in 
control chromosomes) and five polymorphisms (changing in DNA 
sequence that doesn’t modify the aminoacidic sequence or  is present 
also in control chromosome), as shown in tab. 3. The first mutation, 
found in patient II-2 of the first pedigree (Fig.3, panel A) is located in 
exon 10 and is a substitution of a glicine with a proline (A320P) in a 
repeated domain of the protein (Fig.4).  
ATGGTTTACATGGTNCTCCAGGATTCC
ATGGTTTACATGGTGCTCCAGGATTCC
Control
p8
COL19A1 TGGTTTACATGGTGCTCCAGGATTCC
Ala → Pro 320
Fig. 4. Mutation in exon 10 found in one patient affected by esophageal achalasia 
 
The sequencing of COL19A1 in the pedigree didn’t show any 
mutation in the relatives (Fig. 3, panel A). 
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The second mutation, found in patient II-2 (Fig.3, panel B) is a 
deletion of three nucleotides, that cause the deletion of a glutamine at 
position 712 of the protein (Fig.5).  
 
AGGAGAAGNAGGNGNTGCTGNNNCNCCT
Pz p31
GGAGAAGAAGGAGGTGCTGGTGAGCCTCOL19A1
A G G A G A A G A A G G A G G T G C T G G T G A G C C T
Controllo
Three bases delection (GAA) causing a glutamine
loss in pos.712 (GEEGGA→GEGGA). 
                         Fig. 5. Mutation in exon 32 found in one patient affected by esophageal 
achalasia and his homozygous twin. 
 
In this second pedigree, nobody carried the mutation found except 
for subject (II-2), monozygous twin of our patient,  but he wasn’t 
apparently affected by EA (Fig.3, panel B). He will soon undergo an 
esophageal manometry to exclude any functional anomaly. 
Both the mutations found have been tested in 400 control 
chromosome and no one was revealed.  
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Fragment Exon Results 
10 10 One patient  (II-2, Fig.3, panel A): with an heterozygous 
nucleotide substitution G>C (G958C)  
p.A320P  
(1° mutation)  
12 12 Seven patients  with an heterozygous nucleotide 
substitution C>G (C1055G) also present in the control  
chromosome 
p.G355A  
(polymorphism) 
15 15 One patient with a double substitution in heterozygous 
GC>CT in intron 15 (ISV15+10-11GC>CT) 
24 25 Five patients with an heterozygous nucleotide 
substitution G>A (G1689A)  
p.P563P  
(polymorphism) 
Eleven patients with an homozygous thymine insertion in 
position 279482 in intron 25 (ISV25+29insT) 
28 32-33-34 One patient (II-2, Fig.3, panel B) with a three base 
deletion (AGA) in exon 32 (2136-2138delAGA)  
p.E712del  
(2a mutation) 
The same patient carries an heterozygous nucleotide 
substitution in exon 34 C>T (C2289T) present also in 
control chromosome.  
p.G762G,  
(polymorphism) 
39 49 Three patients with a thymine deletion in intron 48 
(ISV48-50delT). 
40 50-51 One patient with a thymine deletion in intron 50 (ISV50-
12delT) 
Tab.3. Polymorphisms and mutations found in COL19A1 
gene in patients affected by EA. 
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Although, two aminoacidic changes found in the patients are absent 
in 400 normal chromosome, the involvement of COL19A1 in the 
pathogenesis of EA in humans still remains to be demonstrated.  To 
this end, it will be necessary to increase number of patient screened 
and to analize the in vitro effects of our mutations maybe by using a 
knock-in animal model.  
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5. INHERITED POLYPOSIS SYNDROMES. 
 
5.1 Clinical and genetics of polyposis in children. 
 
The inherited polyposis syndromes are a group of conditions in 
which multiple gastrointestinal polyps occur in the lumen of the 
gastrointestinal tract. (Tab.4) 
 
Familial adenomatous polyposis 
• Gardner syndrome 
• Turcot syndrome 
• FAP  
 
Hamartomatous syndrome  
• Familial juvenile polyposis 
• Peutz-Jeghers syndrome 
• Codwen syndrome 
• Others (MEN2B, neurofibromatosis, basal cell nevus)       
Tab. 4 Classification of inherited polyposis syndromes 
 
These conditions have an autosomal pattern of inheritance and 
exhibit an increased risk of colon cancer , otherwise benign and 
malignant extraintestinal tumors might be observed. In childhood, 
gastrointestinal polyps are common and are almost always isolated 
benign lesion, but it is very important to make an accurate 
diffential diagnosis between these form and the inherited ones.  
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A fundamental property of normal cellular growth regulation is the 
delicate counterbalance of growth promotion and growth 
inhibition. In the broadest sense, a gastrointestinal polyp results 
from a defect in this highly regulated process. This may occur by 
either aberrant “gain-of-function” in a growth-promoting protein 
(oncogene) or “loss-of-function” in a growth-inhibitory protein 
(tumor suppressor gene). Oncogene are most often activated and 
tumor suppressor gene are most often inactivated, although 
additional molecular and cellular mechanisms favoring polyp 
formation may occur. The genetic gastrointestinal polyposis 
syndromes most often result from a germline (inherited) 
inactivating mutation of a tumor suppressor gene. Eventual somatic 
mutation of the normal remaining allele results in loss of normal 
growth constraint and creates a selective growth advantage, 
unchecked growth and polyp formation. Progression of  a polyp to 
a gastrointestinal cancer requires the sequential acquisition of 
additional genetic defects (fig.6). Recognition of this “adenoma-to-
carcinoma” sequences has been a major advance in the biology of 
gastrointestinal neoplasia (70).  
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Fig. 6. Multi-step carcinogenesis hypothesis  
 
Familial adenomatous polyposis (FAP, OMIM 175100) is 
the most common genetic polyposis syndrome.  Inheritance is 
autosomal dominant, although spontaneous mutations account for 
approximately 30% of cases. The average age at the onset is 16 
years. The occurrence of upper gastrointestinal adenomas confers 
a statically increased risk of duodenal and periampullary 
carcinomas. Progression to neoplasia is considered inevitable by 
the fifth decde in patients with FAP. 
Extra-intestinal manifestations of FAP include desmoids 
tumors, epidermoid cysts, osteomas, congenital hypertrophy of 
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retinal pigment epithelium, fibromas and lipomas, all of which are 
benign, but may signal the presence of FAP in at-risk patients.  
The genetic abnormality in FAP is germline defect in APC, 
a tumor suppressor gene that maps to chromosome 5q21 (71). 
APC is a cytoplasmic protein that binds and regulates the 
degradation of β-catenin, a protein with multiple functions, 
including regulation of cytoskeletal organization, organization of 
tissue architecture, cell migration and adhesion, intracellular 
signaling and gene transcription (72) (Fig. 7).  
 
Fig. 7. Regolazione delle β-catenine da parte di APC normale e mutato 
 
 
Although more than 400 APC mutations have been found, most 
occur in a mutation cluster region located upstream of domains 
responsible for β-catenin degradation. Thus the accumulation of β-
catenin is the likely cellular event leading to tumor development. 
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Correlation exist between the location of mutation in the APC gene 
and the clinical presentation of FAP, as shown in the picture 
(Fig.8). 
 
Some FAP Manifestations Correlate 
With Specific APC Gene Regions
Attenuated FAP
Classic FAP
CHRPE
1 2 3 4 5 6 7 8 9 10111213 14 15
5' 3'
 
Fig. 8. Genotype-Phenotype correlation in FAP. 
 
 
APC mutations can be directly detected in peripheral blood 
lymphocytes by the commercially available in vitro protein 
truncation assays (sensitivity and specificity 80-90%). 
Identification of an APC mutation merits genetic counseling and 
testing of first-degree relatives. Annual flexible sigmoidoscopy 
should be performed in person with a mutant allele. Individuals 
with negative test results but a family member with identified APC 
mutation can be relieved of the burden of annual examinations, 
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because of a cancer risk equivalent to that of the general 
population. Screening of at-risk children should occur at 
approximately age 8 to 10 years.  
 
5.2 Case report published. 
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6. GENE THERAPY IN THE GUT 
Gene therapy is an experimental approach to treat human diseases 
based on the transfer of genetic material to the cells. The transferred 
genetic material can be DNA or RNA. Most commonly it is a 
natural gene but it can also be a chimeric gene or a gene encoding 
for a regulatory RNA. A cell is said to be transduced when it has 
incorporated and expresses a foreign gene (73) To facilitate cell 
transduction, the genetic material is packaged into molecular 
constructs named vectors, which can be of viral (74) and non-viral 
nature(75). 
For a gene to be expressed inside a cell its coding DNA sequence 
should be linked to appropriate regulatory DNA sequences. Gene 
promoters (and other regulatory elements) may allow transgene 
expression in every transduced cell (universal promoters) (76) or, 
alternatively, only in selected cells containing transcription factors 
able to interact specifically with the promoter (as in the case of 
tissue specific promoters)(77) On the other hand, promoters may 
determine a continuous and fixed expression of the transgene in the 
transduced cell or, alternatively, promoter activity can be sensitive 
to certain drugs that when given to the patient can modulate 
promoter function, permitting regulatable expression of the 
transgene (78) The most challenging issues for a successful 
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application of gene therapy to treat human diseases concern the 
choice of the relevant therapeutic gene, of appropriate promoter and 
regulatory sequences and of an effective vector for delivering the 
transgene or trangenes into target cells. Thus gene therapy is a 
matter of genes, vectors, promoters, and regulatory elements. 
Promoter and vector features determine transduction efficacy and 
specificity, duration of transgene expression, and eventually 
appearance of side effects.  
Viral vectors are the most efficient vehicles for gene 
transfer. Different viruses have served to construct gene therapy 
vectors, including adenoviruses(79),  retroviruses (80) (including 
lentivirus), AAV(81), herpesvirus (82), baculovirus(83), SV40 
virus (84), vacciniavirus(85) and others. The list of viral vectors is 
still expanding and modifications of already existing systems will 
increase the number of potential applications of gene therapy. 
Murine retroviruses are single stranded RNA viruses, which after 
interaction with a retrovirus receptor can integrate in the genome of 
a dividing cell. Cells that do not proliferate actively under 
physiological conditions, such as hepatocytes, are difficult to 
transduce with retroviral vectors. Furthermore, transduction 
efficacy is limited by the low titre of virus obtained with the 
production procedures currently used (80). The recent development 
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of human lentiviral (human immunodeficiency virus) based vectors 
offers promising perspectives for gene transfer into non-dividing 
cells 
AAV are non-pathogenic human parvoviruses that, after deletion of 
all viral genes except ITR, have been used successfully as gene 
therapy vectors. AAV vectors do not induce significant immune 
response in animal models and are able to transduce dividing and 
non-dividing cells. The AAV genome persists mainly as episome in 
the target cell nucleus, although a minority of it can integrate in the 
host chromosome (86). After systemic injection AAV demonstrate 
significant liver tropism(87).  
Why could be important to find a strategy to trasduce stably the 
gut? First of all there are a number of disorders of the intestinal 
epithelium that could be amenable to gene therapy. In addition, the 
intestine could be used as an alternative site for the production of 
proteins that need to be secreted to the blood for the correction  of 
disorders such as haemophilia.  
The intestinal tract has many features that make it an attractive 
target for therapeutic gene transfer: (a) easy accessibility via the 
intestinal lumen; (b) large surface area of the epithelium; (c) the 
possibility of in situ gene transfer by endoscopy; (d) known location 
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of stem cells within the intestinal crypt, (e) intestinal cells can 
secrete foreign protein into the circulation. 
As the epithelium turns over rapidly (two to four days), the ideal 
targets for a stable gene transfer would be the intestinal stem cells. 
Permanent gene transfer is conceivable if the gene of interest can be 
integrated into intestinal stem cells. Accessibility of these cells to 
vectors delivered into the intestinal lumen is limited by their deep 
location and by the mucus that lines the epithelium. In vitro 
experiments have shown that intestinal mucus can be solubilised by 
a variety of agents including proteases, detergents, and sulfhydryl 
compounds (88). 
Several methods of gene transfer to the GI tract have been used. 
Most of the techniques target the epithelium but a submucosal 
approach may transduce cells of the muscularis mucosae(89). It has 
been demonstrated in vivo gene transfer to various locations of the 
gastrointestinal tract such as oesophagus, stomach, and colon using 
cationic liposomes.(90,91). Gene transfer was achieved by luminal 
instillation using catheter infusion. A high efficiency of transfection 
was observed in colonic epithelium, with near 100% of epithelial 
cells expressing the transgene. Transgene expression was transient 
and did not persist beyond four days, a finding that is consistent 
with the normal turnover time of gut epithelium.  
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Genes can be transferred into the intestinal epithelium using 
retroviral vectors introduced intraluminally (92). Given the 
continual proliferation of this tissue, these vectors would be an 
appropriate choice because of their ability to transduce dividing 
cells. However, transduction efficiency is comparatively low in the 
intestine of rat and mice and thus retroviral vectors would not 
satisfy the requirements of gene therapy in humans. 
Adenoviral vectors have been shown to transduce intestinal cells in 
vivo when administered through an oral-duodenal tube (93). The 
considerable transduction efficiency of adenoviruses most probably 
reflects the fact that the intestine is a normal site of infection for 
this virus. Transfer of genetic material with adenoviruses is more 
successful in the small intestine as compared with the colon. 
Interestingly, single or repeated challenge with adenoviral vector 
did not cause increased host immune responses to this virus, 
suggesting that this type of vectors could be a good candidate for 
gene therapy of intestinal diseases (93). Also it has been 
demonstrated that adenovirus mediated gene transfer to intestinal 
epithelial cells can effectively deliver proteins to the circulation 
indicating that intestinal cells have the potential to be used as 
heterotopic sites for production of peptidic hormones, cytokines, 
and proteins that should function in plasma (94). 
Genetics of gastrointestinal diseases 
 
71 
 
Another promising vector for gene transfer to the gut is the one 
based on AAV. It has been demonstrated that an orally 
administered AAV vector leads to persistent expression of a β-
galactosidase transgene in both gut epithelial and lamina propria 
cells, and that this approach results in long term phenotypic 
recovery in an animal model of lactose intolerance (95). These data 
were not confirmed by , but considering the hundred different AAV 
serotype today known, with different tropism, we can suppose that 
some of them could have an intestinal tropism and could be useful 
for intestinal gene therapy. 
Another singularity that makes AAV especially suitable as an orally 
delivered vector is its hardiness being very resistant to changes in 
pH and temperature and to solvents. The persistent and stable gene 
expression for almost six months is also another interesting feature. 
As enterocyte turnover is three to five days, this prolonged 
expression indicates that progenitor cells lying within the crypts can 
be transduced by AAV vectors. 
All these features make AAV an attractive vector for GI gene 
transfer with potential application for vaccination purposes and for 
maintained protein replacement, particularly when the release of the 
protein into the portal circulation is a desired goal. 
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6.1 Our experience. 
To trasduce in a stable way the intestinal ephitelium, we performed 
two different strategies: the first was to use serotype of AAV 
different from that already described in the literature (AAV 2/2), 
particularly we used AAV 2/1, 2/5, 2/7, 2/8; the second one 
consisted in the injection of a modified lentivirus, with a Spike 
envelope, that showed a high intestinal tropism when parenteral 
injected. 
In the AAV experiments, we performed a intraduodenal injection of 
of 50-100 x 105 particelles of viral vectors, carring EGFP, in 
C57/BL6 mice at 4 week of life. We sacrificed the animals 4 week 
after the injection and then we analized the expression of EGFP in 
the intestine (duodenum and colon). No differences in the protein 
expression was observed between animals injected with viral vector 
and PBS. 
In the second type of experiments, we used  the modified lentivirus 
vector expressing the LAC-Z protein. We performed again a 
intraduodenal injection (50-100 x 105 particelles) in the same 
condition of the first experiments and then we sacrified the animals 
at 3rd , 21st  and 28th  days from the injection. We collected 
duodenum, ascendant colon and rectum from each animal to X-Gal 
detection.  
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At 3rd day in the duodenum and at 21th day in the rectum we 
observed an increased activity of X-Gal , but we were not able to 
reproduce these results in a second series of experiments, using 
EGFP modified lentivirus vector. 
The most relevant difficulties for the viral vector to trasduce the 
intestinal has probably been the location of the undifferentiated cell, 
located in the deepest part of the crypts,  and maybe the low 
intestinal tropism  of the CMV promoter. So, we are now 
hypnotizing to reduce intestinal obstacles using some molecules 
that can increase intestinal permeability (AT-100) or reduce the 
intestinal mucus. Another aim of our future work will be to create a 
new AAV expressing a different promoter with an higher intestinal 
tropism, such as  intestinal fatty acid binding protein (IFABP), that 
is expressed in the intestinal crypts. 
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Fig. 9. Duodenum from C57/B6 mouse after 3 days of injection of modified 
lentivirus vector expressing LacZ (left) and injected of PBS (right). 
 
 
 
           
Fig. 10. Rectum from  C57/B6 mice after 21 days of injection of modified 
lentivirus vector expressing LacZ (left) and injected of  PBS (right). 
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7. CONCLUSION. 
 
In this thesis we investigated about the clinical and genetic aspects 
of some intestinal dismotility disorders and of inherited poliposis 
syndromes. We  have demonstrated the involvement of FLNA gene 
in the pathogenesis of an X-linked form of intestinal pseudo-
obstruction. We have also hypnotized a possible rule of COL19A1 
gene in the some form of esophageal achalasia. In the future, we 
would like to create animal models for the mutations found to 
elucidate more in details the involvement of these genes in the  
pathogenesis of the studied disorders. 
Furthermore, we have described the clinical phenotype of HSCR 
pediatric patients and we performed the genetic screening of 
SOX10 and ZFX1B in these patients. 
In the last part of the work, we tried to stably trasduce the intestinal 
epithelium using AAV and lentivirus vectors. We would like to 
perform future experiments using substances that are able to 
increase intestinal permeability and to reduce intestinal mucus, so 
that viral vector can easily arrive at the undifferentiated cell in the 
crypts. Otherwise, we will create new AAV vector with a promoter 
(IFABP) with an higher intestinal tropism. 
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